One of the most aggressive forms of breast cancer involves the overexpression of human
epidermal growth factor receptor 2 (HER2). HER2 is overexpressed in∼ 25% of all breast …

Purpose The unique structure of nanobodies is advantageous for the development of
radiopharmaceuticals for nuclear medicine. Nanobodies targeted to human epidermal …

This study developed a probe Fe 3 O 4-Cy5. 5-trastuzumab with fluorescence and magnetic
resonance imaging functions that can target breast cancer with high HER2 expression …

The human epidermal growth factor receptor 3 (HER3) is an interesting target for antitumor
therapy. For optimal HER3 signaling inhibition, a biparatopic Nanobody construct …

Human epidermal growth factor receptor 2 (HER2) status is one of the major tumor
characteristics in breast cancer to guide therapy. Anti-HER2 treatment has clear survival …

Accurate determination of tumor human epidermal growth factor receptor 2 (HER2)‐status in
breast cancer patients is possible via noninvasive imaging, provided adequate tracers are …

The overexpression of human epidermal growth factor 2 (HER2) in breast cancer (BC) has
been associated with a more aggressive tumor subtype, poorer prognosis and shorter …

The human growth factor receptor type 2 (HER2) is overexpressed in breast as well as other
types of cancer. Immuno-PET, a noninvasive imaging procedure that could assess HER2 …

Introduction Radiolabeled nanobodies are exciting new probes for molecular imaging due to
high affinity, high specificity and fast washout from the blood. Here we present the labeling of …

Objectives Nanobodies (Nbs) are the smallest antibody-derived fragments with beneficial
pharmacokinetic properties for molecular imaging and radionuclide therapy. Human …